Infant Bacterial Therapeutics AB

IBT B

SE0008015259

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:22:34 2024-04-26 am EDT			5-day change	1st Jan Change
87.8 ^SEK	+0.46%		+4.03%	-2.44%

Feb. 08	Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 08	Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 08, 2024 at 02:30 am EST

Infant Bacterial Therapeutics AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was SEK 40.89 million compared to SEK 40.12 million a year ago. Basic loss per share from continuing operations was SEK 3.04 compared to SEK 3.57 a year ago.

Latest news about Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Infant Bacterial Therapeutics AB Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024	23-10-24	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Sweden’s Infant Bacterial Therapeutics to Raise SEK101 Million via Rights Issue	23-07-04	MT
Infant Bacterial Therapeutics AB Announces Data Monitoring Committee Performs the Planned Safety Analysis of the Study Data of 1,403 Babies	23-06-21	CI
Infant Bacterial Therapeutics AB Continues to Recruit Precious to Its Connection Study	23-06-21	CI
Infant Bacterial Therapeutics AB Announces New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe	23-06-15	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Infant Bacterial Therapeutics Announces Opening of Final Infant Cohort Will Accelerate Patient Recruitment	23-03-22	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-10	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-10	CI
Infant Bacterial Therapeutics AB Publishes Clinical Findings in British Journal of Gastroenterology	23-01-24	CI
Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections	23-01-12	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Infant Bacterial Therapeutics AB Announces Nomination Committee Appointments	22-11-04	CI
Infant Bacterial Therapeutics Secures US FDA Orphan Drug Designation For Retinopathy Of Prematurity Treatment	22-09-23	MT
FDA Approves Infant Bacterial Therapeutics' Request for a New Orphan Drug Designation	22-09-23	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Infant Bacterial Therapeutics AB Appoints Maria Ekdahl as Chief Financial Officer, Effective September 19, 2022	22-06-30	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Infant Bacterial Therapeutics AB Announces Management Changes	22-05-04	CI
Infant Bacterial Therapeutics AB Announces Retirement of Michael Owens as CFO	22-05-04	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-04	CI

Chart Infant Bacterial Therapeutics AB

Duration

Period

More charts

Company Profile

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Companyâs focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
INFANT BACTERIAL THERAPEUTICS AB	-2.44%	108M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B